2022 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Welcome to the latest of our Eberhard F. Mammen Award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2022 represents in excess of 10 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:

• ● Most popular article awards: Awarded to the authors of the most popular articles published in STH. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, errata, letters to the editor, editorials, commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Open Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “free to download” status for these articles thereafter.

• ● Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the current coronavirus disease 2019 (COVID-19) pandemic, many international congresses have become virtual meetings, and accordingly, virtual meeting presentations can also be considered for the award.

Fig. 1 Eberhard F. Mammen (1930–2008).

Table 1 Previous editorials related to Eberhard F. Mammen Award announcements

1. Favaloro EJ. Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008;34:693–696 2. Favaloro EJ. A Tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008;34:703–708 3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009;35:1–2 4. Favaloro EJ. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. Semin Thromb Hemost 2009;35:587–590 5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. Semin Thromb Hemost 2010;36:469–470 6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009. Semin Thromb Hemost 2010;36(7):685–692 7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011;37(5):431–439 8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012;38:425–432 9. Favaloro EJ. 2013 Eberhard F. Mammen award announcements. Semin Thromb Hemost 39:567–574 10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: Part I - most popular articles. Semin Thromb Hemost 2014;40(4):407–412 11. Favaloro EJ. 2014 Eberhard F. Mammen Award Announcements: Part II - Young Investigator Awards. Semin Thromb Hemost 2014;40(7):718–723 12. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2015;41(7):673–679 13. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2015;41(8):809–815 14. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2016;42(4):325–330 15. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2017;43(3):235–241 16. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2017;43(4):357–363 17. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2018;44(2):81–88 18. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2018;44(3):185–192 19. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2019;45(2):123–129 20. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2019;45(3):215–224 21. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2020;46(2):105–113 22. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2020;46(4):383–392 23. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2021;47(3):229–237 24. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2021;47(5):467–476 25. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2022;48(3):265–273

Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print ([Table 1]). This includes the recent announcement of the 2021 Young Investigator Awards.[1]

It is therefore with great pleasure that we would like to announce the latest winners of the 2022 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2020 to 2021 inclusive.

Publikationsverlauf

Artikel online veröffentlicht:
14. Juni 2022

• References

• 1 Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2022;48(03):
• 2 Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020; 46 (07) 763-771
• 3 Allaoui A, Khawaja AA, Badad O. et al. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021; 47 (04) 419-426
• 4 Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost 2020; 46 (03) 275-288
• 5 Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost 2020; 46 (03) 302-319
• 6 Zadow EK, Wundersitz DWT, Hughes DL. et al. Coronavirus (COVID-19), coagulation, and exercise: interactions that may influence health outcomes. Semin Thromb Hemost 2020; 46 (07) 807-814
• 7 Christensen B, Favaloro EJ, Lippi G, Van Cott EM. Hematology laboratory abnormalities in patients with coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 2020; 46 (07) 845-849
• 8 Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost 2020; 46 (07) 796-803
• 9 Fernández-Capitán C, Barba R, Díaz-Pedroche MDC. et al. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. Semin Thromb Hemost 2021; 47 (04) 351-361
• 10 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45 (01) 86-93
• 11 Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment of the New Roche Cobas t 711 fully automated coagulation analyzer. Semin Thromb Hemost 2019; 45 (03) 308-314
• 12 Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in european and north american patients infected with COVID-19: a meta-analysis. Semin Thromb Hemost 2021; 47 (04) 392-399
• 13 Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021; 47 (04) 372-391
• 14 Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost 2019; 45 (03) 275-284
• 15 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
• 16 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35 (02) 189-203
• 17 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (08) 709-733
• 18 Orsi FA, Cannegieter SC, Lijfering WM. Statin therapy to revert hypercoagulability and prevent venous thromboembolism: a narrative review. Semin Thromb Hemost 2019; 45 (08) 825-833
• 19 van der Vorm LN, Huskens D, Kicken CH. et al. Effects of repeated bouts of exercise on the hemostatic system. Semin Thromb Hemost 2018; 44 (08) 710-722
• 20 Stillson JE, Bunch CM, Gillespie L. et al. Thromboelastography-guided management of anticoagulated COVID-19 patients to prevent hemorrhage. Semin Thromb Hemost 2021; 47 (04) 442-446
• 21 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2014; 40 (03) 277-283
• 22 Bezuidenhout JA, Pretorius E. The central role of acute phase proteins in rheumatoid arthritis: involvement in disease autoimmunity, inflammatory responses, and the heightened risk of cardiovascular disease. Semin Thromb Hemost 2020; 46 (04) 465-483
• 23 Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention of cardiovascular disease: a narrative overview. Semin Thromb Hemost 2019; 45 (02) 157-163
• 24 Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021; 47 (04) 400-418
• 25 Favaloro EJ, Pasalic L, Curnow J. Type 2M and type 2A von Willebrand disease: similar but different. Semin Thromb Hemost 2016; 42 (05) 483-497
• 26 Leiderman K, Sindi SS, Monroe DM, Fogelson AL, Neeves KB. The art and science of building a computational model to understand hemostasis. Semin Thromb Hemost 2021; 47 (02) 129-138
• 27 Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 2020; 46 (08) 932-969
• 28 Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Fibrinogen supplementation and its indications. Semin Thromb Hemost 2020; 46 (01) 38-49
• 29 Black JA, Pierce VS, Kerby JD, Holcomb JB. The evolution of blood transfusion in the trauma patient: whole blood has come full circle. Semin Thromb Hemost 2020; 46 (02) 215-220
• 30 Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost 2019; 45 (04) 321-325
• 31 Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost 2017; 43 (03) 270-276
• 32 Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 2017; 43 (03) 253-260
• 33 Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost 2020; 46 (08) 865-871
• 34 Abeysiri S, Chau M, Richards T. Perioperative anemia management. Semin Thromb Hemost 2020; 46 (01) 8-16
• 35 Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost 2019; 45 (06) 604-611
• 36 Levi M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost 2019; 45 (04) 342-347
• 37 Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin Thromb Hemost 2017; 43 (04) 386-396
• 38 Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 2019; 45 (01) 22-35
• 39 Fang ZA, Navaei AH, Hensch L, Hui SR, Teruya J. Hemostatic management of extracorporeal circuits including cardiopulmonary bypass and extracorporeal membrane oxygenation. Semin Thromb Hemost 2020; 46 (01) 62-72
• 40 Marongiu F, Mameli A, Grandone E, Barcellona D. Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism?. Semin Thromb Hemost 2019; 45 (08) 778-783
• 41 Babin JL, Traylor KL, Witt DM. Laboratory monitoring of low-molecular-weight heparin and fondaparinux. Semin Thromb Hemost 2017; 43 (03) 261-269
• 42 Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost 2017; 43 (08) 849-863
• 43 Mensah PK, Pavord S. Managing preoperative hemostasis in patients with inherited and acquired bleeding disorders. Semin Thromb Hemost 2020; 46 (01) 17-25
• 44 Lippi G, Danese E, Favaloro EJ. Vascular disease and dementia: lipoprotein(a) as a neglected link. Semin Thromb Hemost 2019; 45 (05) 544-547
• 45 Tabibian S, Shiravand Y, Shams M. et al. A comprehensive overview of coagulation factor V and congenital factor V deficiency. Semin Thromb Hemost 2019; 45 (05) 523-543
• 46 Nikolakopoulos I, Spyropoulos AC. Heparin bridging therapy for patients on chronic oral anticoagulants in periprocedural settings. Semin Thromb Hemost 2020; 46 (01) 26-31
• 47 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (08) 865-883
• 48 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (05) 579-589
• 49 Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40 (05) 571-576
• 50 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (04) 349-356
• 51 Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32 (Suppl. 01) 3-15
• 52 Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2021; 47 (05) 467-476
• 53 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part I. Semin Thromb Hemost 2020; 46 (07) 757-762
• 54 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part II. Semin Thromb Hemost 2021; 47 (04) 333-337
• 55 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part III. Semin Thromb Hemost 2022; 48 (01) 3-7
• 56 Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost 2021; 47 (07) 759-774
• 57 Favaloro EJ, Lippi G. Editorial compilation VII. Semin Thromb Hemost 2019; 45 (05) 429-432
• 58 Hunt BJ, Levy JH. Perioperative thrombosis and hemostasis. Semin Thromb Hemost 2020; 46 (01) 6-7
• 59 Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2018; 44 (02) 81-88
• 60 Russo V, Attena E, Mazzone C. et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018; 44 (04) 364-369
• 61 Favaloro EJA. A 2018 update on the editorial and publication policy of seminars in thrombosis and hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
• 62 Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2020; 46 (04) 383-392
• 63 Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. Semin Thromb Hemost 2021; 47 (03) 229-237